We are live on ! Find out more
GWPH

GW Pharmaceuticals Plc American Depositary Shares
GWPH

Delisted

GWPH was delisted on the 4th of May, 2021.

204 hedge funds and large institutions have $3.03B invested in GW Pharmaceuticals Plc American Depositary Shares in 2017 Q4 according to their latest regulatory filings, with 51 funds opening new positions, 53 increasing their positions, 59 reducing their positions, and 26 closing their positions.

New
Increased
Maintained
Reduced
Closed

96% more first-time investments, than exits

New positions opened: 51 | Existing positions closed: 26

44% more capital invested

Capital invested by funds: $2.1B → $3.03B (+$927M)

20% more funds holding in top 10

Funds holding in top 10: 56 (+1)

13% more funds holding

Funds holding: 181204 (+23)

10% less repeat investments, than reductions

Existing positions increased: 53 | Existing positions reduced: 59

12% less call options, than puts

Call options by funds: $75.8M | Put options by funds: $85.9M

Holders
204
Holders Change
+23
Holders Change %
+12.71%
% of All Funds
4.63%
Holding in Top 10
6
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+20%
% of All Funds
0.14%
New
51
Increased
53
Reduced
59
Closed
26
Calls
$75.8M
Puts
$85.9M
Net Calls
-$10M
Net Calls Change
+$16.7M
Name Holding Trade Value Shares
Change
Change in
Stake
Brown Advisory
126
Brown Advisory
Maryland
$224K +$199K +1,696 New
DWA
127
Douglass Winthrop Advisors
New York
$215K +$191K +1,625 New
1WA
128
180 Wealth Advisors
Washington
$214K +$191K +1,622 New
CG
129
Cutler Group
California
$211K -$319K -2,711 -63%
AG
130
Advisor Group
Arizona
$187K -$7.87K -67 -5%
APA
131
American Portfolios Advisors
New York
$175K +$156K +1,327 New
QT
132
Quantbot Technologies
New York
$118K +$47.7K +406 +83%
CAM
133
Close Asset Management
United Kingdom
$110K
IA
134
IFP Advisors
Florida
$92K -$48.6K -414 -37%
Zurich Cantonal Bank
135
Zurich Cantonal Bank
Switzerland
$90K
IWM
136
IHT Wealth Management
Illinois
$87K
DCM
137
Delpha Capital Management
New York
$83K +$74K +630 New
EDRH
138
Edmond de Rothschild Holding
Switzerland
$79K
BBHC
139
Brown Brothers Harriman & Co
New York
$73K +$65K +553 New
SPIA
140
Steward Partners Investment Advisory
New York
$67K
AAMU
141
Amundi Asset Management US
Massachusetts
$66K +$58.8K +500 New
JP Morgan Chase
142
JP Morgan Chase
New York
$62K -$975K -8,300 -95%
KF
143
Krilogy Financial
Missouri
$56K -$47K -400 -48%
RIA
144
RPG Investment Advisory
California
$53K +$9.99K +85 +27%
HNB
145
Huntington National Bank
Ohio
$43K
FGC
146
Financial Gravity Companies
Texas
$43K +$36.5K +311 New
AIM
147
Advantage Investment Management
Iowa
$40K +$29.4K +250 +500%
SWP
148
Stratos Wealth Partners
Ohio
$40K +$35.3K +300 New
ASN
149
Advisory Services Network
Georgia
$37K +$13.5K +115 +71%
SAM
150
Solaris Asset Management
New York
$33K

GWPH Hedge Fund Activity: Q4 2017 in Review

204 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in GW Pharmaceuticals Plc American Depositary Shares (GWPH) for Q4 2017, worth a combined $3.03B — up 44% from $2.1B a quarter earlier.

Buyers outnumbered sellers: 51 funds opened new GWPH positions and 26 closed out — a net gain of 25 holders — while 53 added to existing stakes and 59 trimmed.

The largest buyer was Capital World Investors, adding an estimated $89.3M. The largest seller was OrbiMed, cutting an estimated $60.7M.

  • 204 institutional investors held GW Pharmaceuticals Plc American Depositary Shares (GWPH) as of Q4 2017, up from 181 in Q3 2017.
  • Funds reported $3.03B of GW Pharmaceuticals Plc American Depositary Shares stock for Q4 2017, up 44% quarter-over-quarter.
  • 51 funds opened new GW Pharmaceuticals Plc American Depositary Shares positions in Q4 2017 and 26 closed out, a net change of +25 holders.
  • The largest GW Pharmaceuticals Plc American Depositary Shares buyer in Q4 2017 was Capital World Investors, an estimated $89.3M added.
  • The largest GW Pharmaceuticals Plc American Depositary Shares seller in Q4 2017 was OrbiMed, an estimated $60.7M sold.

Based on aggregated 13F filings for Q4 2017.